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Therapeutic interfering particles 
exploiting viral replication 
and assembly mechanisms 
show promising performance: 
a modelling study
Farzad Fatehi1,2,6, Richard J. Bingham1,2,3,6, Pierre‑Philippe Dechant1,2,4,6, 
Peter G. Stockley5* & Reidun Twarock1,2,3*
Defective interfering particles arise spontaneously during a viral infection as mutants lacking essential 
parts of the viral genome. Their ability to replicate in the presence of the wild‑type (WT) virus (at the 
expense of viable viral particles) is mimicked and exploited by therapeutic interfering particles. We 
propose a strategy for the design of therapeutic interfering RNAs (tiRNAs) against positive‑sense 
single‑stranded RNA viruses that assemble via packaging signal‑mediated assembly. These tiRNAs 
contain both an optimised version of the virus assembly manual that is encoded by multiple dispersed 
RNA packaging signals and a replication signal for viral polymerase, but lack any protein coding 
information. We use an intracellular model for hepatitis C viral (HCV) infection that captures key 
aspects of the competition dynamics between tiRNAs and viral genomes for virally produced capsid 
protein and polymerase. We show that only a small increase in the assembly and replication efficiency 
of the tiRNAs compared with WT virus is required in order to achieve a treatment efficacy greater than 
99%. This demonstrates that the proposed tiRNA design could be a promising treatment option for 
RNA viral infections.
Viruses are a major burden for public health and economy, yet our repertoire of antiviral options is still very 
limited. This is, in part, due to the high frequency with which viral genomes mutate and thus evade treatment. 
On the other hand, these mutations can sometimes lead to the production of defective viral genomes (DVGs) 
which are shed in defective interfering particles (DIPs). DVGs are spontaneously occurring mutants in a viral 
infection that lack essential genetic information, e.g. through deletion mutations, but are capable of replicating 
in the presence of, and indeed at the expense of, resources produced by  viruses1, 2. Many DVGs are well-known 
to have a replicative advantage over WT and to play a role in interference with WT  virus3, 4, virus  persistence5 as 
well as  specific6 and unspecific immune  activation5, 7. The exploitation of DIPs is a promising recent approach 
for  therapy6, 8, 9. DIPs are selected and amplified for therapeutic use facilitated by advanced cloning  techniques6, 
10–14, and have progressed to the  clinic10, 15–17.
Von Magnus was the first to report the occurrence of DIPs, seen in influenza A virus populations passaged 
in embryonated chicken  eggs18. Subsequently, in a prolonged persistence of vesicular stomatitis virus infections, 
mediated by WT DIPs, mutants (called Sdi− mutants) were detected that are WT DIP resistant, demonstrating 
the importance of selection for DIP  populations19. DIPs have been reported to cause oscillations in virus  levels20. 
Zwart et al.21 developed a simple mathematical model of baculovirus-DI dynamics which qualitatively repro-
duced the oscillatory patterns seen in experimental data. DIPs engineered for therapy were designed to spread 
between individuals and autonomously target high-risk groups for HIV and it has been argued that this method 
could decrease HIV/AIDS prevalence by 30-fold in 50  years22, 23. The impact of these transmissible antivirals are 
studied in intracellular, within-host, and epidemiological  models24, 25.
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We propose here a novel strategy that exploits our discovery of packaging signal (PS)-mediated assembly in 
single-stranded RNA (ssRNA) viruses for the design of therapeutic interfering RNAs (tiRNAs) which are pack-
aged into therapeutic interfering particles (TIPs) mimicking essential features of these DIPs. The genomes of 
many RNA viruses, including bacteriophages, plant viruses, and human pathogens present multiple dispersed 
sequence/structure motifs (PSs) that share a core recognition motif for the viral coat protein (Cp). Sequence 
variation around that core motif confers differential levels of affinity for Cp to the PSs, creating a hierarchy of 
affinities across the genome-embedded PS ensemble. This enables PSs to recruit Cp to the growing capsid shell, 
collectively promoting virus  assembly26–32 (Fig. 1a).
Stochastic simulations of virus assembly reveal that the differences in affinity at distinct PS sites are important, 
because they bias the number of possible assembly pathways to a small number of dominant ones with very 
similar geometric properties, resulting in higher yields of fully assembled capsids compared with PS distributions 
lacking this variation. They also ensure specific encapsidation in the context of cellular competitor RNAs. This 
means that PSs enable the virus to overcome the equivalent of Levinthal’s Paradox in protein folding. The latter 
refers to the complexity of protein folding, which would require an unrealistically long time to complete if it 
solely relied on a random exploration of all combinatorially possible pathways. Similarly, the assembly of a viral 
capsid would be too slow in the arms race against host defence mechanisms if it were exploring all geometrically 
possible pathways, rather than the subset favoured due to interaction with the  PSs33. In some cases, such as in the 
Picornavirus human parechoviruses (HPeV), the PSs and their Cp binding sites have been characterised to atom-
istic  detail32. They have also been identified in hepatitis B  virus30, 34, a DNA virus that packages its genome into its 
capsid in the form of pre-genomic RNA. Our detailed mechanistic understanding of PS-mediated assembly has 
Figure 1.  Assembly and intracellular dynamics of vRNAs and tiRNAs. (a) The PS-mediated assembly 
paradigm: Multiple sequence/structure motifs called packaging signals (PSs), that are dispersed throughout 
the viral genome, promote virion assembly via sequence specific interactions with coat protein (Cp). (b) vRNA 
and tiRNA in comparison: tiRNA is similar to vRNA but is devoid of any genetic message. (c) Schematic 
representation of the mathematical model for vRNA (red) and tiRNA (blue) in an HCV infection: In step 1 and 
2; vRNA in the cytoplasm binds to free ribosomes to form a translation complex, which synthesizes the viral 
polyprotein (PP). The latter is cleaved, leading to the production of structural proteins such as core protein (Cp) 
and nonstructural proteins, including NS3/4A, NS5A, and NS5B. In step 3; NS5B and NS5A bind to vRNA or 
tiRNA and host factor (HF), respectively. These two complexes are imported into the vesicular membranous 
structure (VMS). In step 4; the imported RNAs form double-strand RNAs (dsRNAs) and release NS5B and HF. 
In step 5; dsRNAs again bind to the NS5B and synthesise new vRNAs and tiRNAs. In step 6; these RNAs are 
either exported into the cytoplasm, or assembled into virions with 180 Cp and exported from the cell. (d) The 
time evolution of the HCV infection model shows the cumulative number of released virions (solid red line) 
and total vRNA (dashed red line), averaged over 250 simulations with the initial condition (+) RNAcyt =1 and 
Cp=180. (e) The dynamics of virions and TIPs, where the solid red and blue lines indicate the released virions 
and TIPs, respectively, and the dashed red and blue lines the total vRNAs and tiRNAs, respectively, with the 
initial condition (+) RNAcyt=1, (+) tiRNAcyt =1 and Cp=360. The shaded areas highlight the regions of one 
standard deviation (std) from the mean. (d) and (e) are plotted using parameter values from Table 1 with ba = 1 
and br = 1.
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enabled us to optimise the assembly code in satellite tobacco necrosis virus (STNV), creating RNA mutants that 
outcompete viral genomes in a competition  assay35. Many of the best-studied examples of DVGs are found in (-)
ssRNA viruses, which are presently known not to assemble via multiple dispersed PSs. For viruses assembling via 
multiple dispersed PSs, indeed DIPs that are assembly competent and competitive with WT may not spontane-
ously arise through the standard  mechanisms5; however, using our new mechanistic understanding they could 
be engineered. Here we propose to decouple the assembly code from the genetic message, and create synthetic 
assembly substrates containing only the PS-encoded virus assembly instructions allowing them to be efficiently 
encapsulated by viral Cp. To mimic the naturally occurring DIPs, we also include a recognition signal for viral 
replicase into our de novo designed tiRNAs, so that they are replicated by viral replicase (Fig. 1b). Although some 
naturally occurring DIPs for influenza  A6 or Zika  virus8 have internal ribosome entry site (IRES), we deliberately 
exclude such IRESs here in order to give tiRNAs another competitive advantage over vRNAs by not spending 
time on translation. An added advantage is that the presence of IRESs, and consequently interactions between 
ribosomes and IRES containing tiRNAs, would trigger an immune response that could lead to the removal of 
the cell, unnecessarily increasing tissue damage.
Mathematical models of a viral infection can be used to assess the merits of novel antiviral  strategies34, 36. 
The population dynamics of DIPs interacting with WT virus (called the ‘helper’ or ‘standard’ virus) can be 
 complicated37–40 with chaotic or predator-prey dynamics, but often the parasitic relationship between DIPs and 
helper virus results in the attenuation or clearance of the original infection. Thus, we use HCV (an ssRNA virus) 
as a model system and we develop an extension of an intracellular model of HCV presented by Aunins et al.41 
that now includes also the dynamic competition between tiRNAs and viral RNAs (vRNAs).
Intracellular modelling of HCV infection and tiRNAs
Recently Aunins et al. presented a detailed, parameterised intracellular model for hepatitis C viral (HCV) infec-
tion based on experimental  data41. The model consists of 6 steps (Fig. 1c). Step 1; positive-sense RNA strand 
in the cytoplasm [(+)RNAcyt ] binds to free ribosomes to form a translation complex (R:(+)RNA) at a rate ktc , 
which synthesizes the viral polyprotein (PP) at a rate ktrans . Step 2; the cleavage of PPs at a rate kcleavage leads to 
production of structural proteins, including core protein (Cp) and nonstructural proteins, including NS3/4A, 
NS5A, and NS5Bcyt . Step 3; NS5Bcyt (polymerase) and NS5A bind to (+)RNAcyt and host factor (HF) at rates krp5b 
and khfc to form NS5B:(+)RNA and HFC complexes, respectively. These two complexes are imported into the 
vesicular membranous structure (VMS) at a rate krip in a second-order reaction. Step 4; the imported RNA forms 
a double-strand RNA (dsRNA) and releases NS5BVMS and HF at a rate kinit . Step 5; dsRNA binds to the NS5BVMS 
at a rate krids to synthesise (+)RNAVMS at a rate krepl . Step 6; (+)RNAVMS in the VMS are either exported into the 
cytoplasm at a rate koutrp , or assembled into virions with 180 Cp and exported from the cell at a rate kassembly . 
The model was fitted to experimental data and estimated parameter values (Table 1)41.
In this paper, we extend this model to include the dynamics of tiRNAs (Fig. 1c). Both the viral genome and 
tiRNA assemble via packaging signal (PS)-mediated assembly, i.e. both present PSs with affinity for viral Cp, 
ensuring efficient, specific genome packing. The PS distribution of the tiRNAs is optimised with respect to that 
of the virus, e.g. by stabilising key PSs in the distribution as  in35, enabling them to potentially assemble more 
efficiently than the virus (Fig. 1a). We consider tiRNAs which also contain the terminal sequences necessary for 
recognition by viral  polymerases6, 42, 43, so that they are replicated in the presence of the virus (Fig. 1b). As there 
is no protein coding requirement, and indeed no IRES, tiRNAs replication efficiency relative to the genome can 
be increased by shortening of the genome, or by tuning the nucleotide  sequence42, 43. Thus, we model tiRNAs 
dynamics as follows: We assume that a positive-sense tiRNA in the cytoplasm [(+)tiRNAcyt ] binds to NS5Bcyt and 
HFC at rates krp5b and krip , respectively, to be imported into the VMS. Then, similar to viral RNAs (vRNAs), they 
produce double-strand tiRNA and (+)tiRNAVMS at rates brkinit and brkrepl , respectively, where br characterises 
the replication efficiency of the tiRNAs. A tiRNA with br = 1 would be transcribed at the same rate as vRNAs. 
The newly formed (+)tiRNAVMS is then either exported into the cytoplasm at a rate koutrp or assembled into 
TIPs with 180 Cp and exported from the cell at a rate bakassembly , where ba characterises the assembly efficiency 
of the tiRNAs (Fig. 1c). The assembly efficiency of a tiRNA can be tuned by alteration of the PS distribution, for 
instance, a competition experiment between STNV and a copy with an optimised PS distribution resulted in 
encapsidation in a ratio of 1 : 2 to 1 :  335, suggesting that ba ∼ 2.5 is experimentally achievable. The reactions of 
the model are provided in Methods.
Aunins et al.41 used ordinary differential equations (ODE) to model the production of virions over a relatively 
short timescale (50 hours). In this work we derive a continuous-time Markov chain (CTMC) model from the 
ODE  model44, 45 and use the Gillespie algorithm as a discrete stochastic method for solving the CTMC model and 
plot stochastic  trajectories46. The mean over the stochastic trajectories plotted using the Gillespie algorithm is 
in excellent agreement with the ODE dynamics (Supplementary Figure S1 online). However, using the Gillespie 
method will also enable the tracking of individual particles, which is of particular interest at low concentrations 
during the initial kinetic  phase34. As the average life span of adult hepatocytes ranges from 200 to 300  days47 and 
since the half-life of HCV infected cells is estimated to be between 1.4 and 700  days48, we ran our simulations 
for 100 days.
Results
Single cell viral dynamics. Here we study the viral dynamics in the absence and presence of tiRNAs. The 
dynamics are computed as an average over 250 stochastic simulations of the reaction network using the Gillespie 
 algorithm46 implemented in Fortran and using parameter values from Table 1 and initially, with ba = 1 and 
br = 1 . The multiplicity of infection (MOI) is set to one vRNA and one tiRNA, consistent with data for intranasal 
sprays for clonal influenza  DIPs6. Figure 1d indicates the total number of released virions (solid red line) and 
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vRNAs in the cell (dashed red line) in the absence of co-infecting tiRNAs. Figure 1e shows the effect on viral 
dynamics of introducing tiRNAs. Co-infection with tiRNAs reduces the level of released virions by 70%. This 
reduction in the total number of released virions is called the treatment efficacy. It is here reached within 3 days, 
and remains within 2% of this value thereafter. The number of tiRNAs within the cell is comparable with the 
level of vRNAs in the tiRNA-free case. This shows that even without an advantage in replication or assembly, the 
lack of a protein-coding responsibility (and an IRES) enables tiRNAs to displace vRNAs as the most frequently 
packaged contents of new virus-like particles (VLPs).
The impact of the tiRNAs relies on two characteristic features: their relative replication ( br ) and assembly 
( ba ) efficiency compared with helper virus. We therefore investigate the impact of these two descriptors on the 
infection dynamics.
The effects of replication and assembly efficiencies. The assembly and replication efficiency of tiR-
NAs can be increased by adding more PSs into the genome, stabilising PSs or increasing their binding affinity, 
and shortening of the genome, respectively (Fig. 2a). Though many DVGs are well-known to have a replicative 
advantage over WT, probably due to their shorter  genomes5, 8, 49, the length of the genome is not the only fac-
tor that determines the replication efficiency ( br)43, 50. Thus, we also consider the cases where br < 1 , i.e., when 
tiRNAs are replicating less efficiently than WT virus. Figure 2b shows, for br < 0.7 , that the efficacy of tiRNAs 
remains below 50%, even for high values of ba (assembly efficiency). This illustrates the importance of the rep-
lication process in the viral life cycle, as tiRNAs must be at least as efficient as WT virus at replication to be a 
viable treatment option. For br ≤ 1 , i.e. if tiRNAs are not more efficient at replication than virus, the total num-
ber of released particles is lower than the tiRNA-free control. For br > 1 the total number of released particles 
increases, but these are overwhelmingly dominated by TIPs (Fig. 2c). This increase in the number of TIPs will 
increase the level of antigen and could have consequences for the immune response. However, increasing of ba 
alone does not lead to an increase in the level of total released particles (Fig. 2c). As the length of the genome is 
not the only factor impacting br , we have done our analysis for varying values of br . We note that there are some 
naturally occurring DVGs that are 30% shorter than the WT genome. If br were related to length linearly, this 
would give br = 1.4288. Thus, considering values up to br = 2 for the de novo designed tiRNAs seems achievable. 
Figure 2.  The impact of replication and assembly efficiencies on the treatment efficacy and cumulative number 
of released virus-like particles. (a) TIP design is defined by two parameters: assembly efficacy ba , which can 
be changed by addition of PSs in the tiRNAs (blue) compared with vRNA (red), and replication efficacy br , 
which can be improved by shortening of tiRNA with respect to vRNA. (b) The efficacy of tiRNAs (shown as 
the fraction indicating reduction in the number of released infectious virions) as a function of ba and br . (c) 
Pie charts for the cumulative number of released virions and TIPs after 100 days post infection. Red and blue 
indicate virions and TIPs, respectively. The tiRNA-free control is shown for comparison. The area of each graph 
is proportional to the total number of released particles (virion+TIP) with respect to the control. For br ≤ 1 the 
total number of released particles is less than the control, while for br = 2 the total number of released particles 
is 3 times that of the control. (b) and (c) are plotted by averaging over 250 simulations with the initial condition 
(+)RNAcyt = 1 , (+)tiRNAcyt = 1 and Cp = 360 , using parameter values from Table 1.
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Interestingly, the benefits of the treatment have a saturation point; increasing ba > 10 and increasing br > 2 does 
not have a significant impact on the efficacy of the treatment and total number of released particles (Fig. 2b and 
c).
Even for ba = br = 1 , i.e. for equal replication and assembly efficiency as the virus, the number of released 
TIPs is higher than that of infectious virions. This is because tiRNAs have a competitive advantage over virus as 
they are depleting resources generated only by the virus, using virally generated polymerase for replication and 
Cp for assembly. In particular, during the time that vRNA is bound to ribosome, tiRNA is free to bind to NS5B 
and replicate at the expense of the virus, resulting in the inherent asymmetry between virus and TIP.
The effect of higher multiplicities of infection (MOIs). The above results have been obtained in the 
equitable case of an MOI of 1:1. Experimental work on comparable systems have reported DIP MOIs in the 
range 1–1006, 39, 51. Therefore, we also consider cases with unequal starting proportions of vRNA and tiRNA. 
We determine the release kinetics for higher MOIs, setting ba = br = 1 in order to isolate the effect of the MOI.
For MOIs of tiRNA (T) higher than the MOI of vRNA (V), the number of released virions decreases while 
increasing the ratio of TIPs/Virions (Fig. 3), with TIPs swiftly dominating the population. However, for MOIs 
of vRNA larger than the MOI of tiRNA, a much smaller effect occurs (Fig. 3) and virions outnumber the TIPs, 
demonstrating that the relative ratio of virus and TIPs is important for the treatment outcome. From Fig. 3 we 
can see that when the MOI of tiRNA and vRNA is equal V = T = 1, the released particles are dominated by 
TIPs in, roughly, a 1.5:1 ratio with the virions. This suggests that in a population of infected cells, the subsequent 
infections would also be seeded by MOIs with more tiRNAs than vRNAs, moving rightward in Fig. 3. This leads 
to a population of released particles dominated by non-infectious TIPs, potentially causing the elimination of 
the wider infection. A within-host model of an HCV infection in the presence of tiRNAs is required to fully 
examine the potential of this treatment strategy.
The effect of treatment start time. The results presented above are based on the assumption that both 
the vRNAs and the tiRNAs begin the infection at the same time. However, this would not necessarily be the case 
in vivo. Figure 4 shows that if the MOI of tiRNA is larger than that of vRNA (blue shaded area), then the efficacy 
is higher than the average efficacy (solid black line). On the other hand, if the MOI of vRNA is larger than that 
of tiRNA (red shaded area), then the efficacy is lower than the average efficacy. If each cell being infected by a 
vRNA already harbours at least one tiRNA (start of treatment = 0 hour), we get the highest treatment efficacy 
(Fig. 4). However, if treatment was started (i.e. the tiRNAs introduced) after 24 h post infection, this treatment 
option has no significant effect on the outcome of the infection even if ba , br are high and the MOI of tiRNAs is 
greater than that of the vRNAs. This is because there are more than 1,000 vRNAs in the cell, so that tiRNAs have 
little chance to overtake the viral life cycle (Fig. 4). This suggests that tiRNAs can be highly effective when used as 
a prophylactic antiviral treatment, an approach that has recently gained wider  attention6, 52. Recent experiments 
for influenza DIPs have established that prophylactic intranasal treatment can achieve delivery of around one 
DIP per susceptible cell, where they can stay present for several  weeks6. Although evaluation of the full impact of 
Figure 3.  Pie charts for the cumulative number of released virions and TIPs 100 days post infection. Increasing 
the MOI of tiRNA (T) increases the cumulative number of released TIPs and reduces the total number of 
released particles (virion+TIP) compared with the control. Red and blue indicate the number of virions and 
TIPs, respectively, while white shows the difference between the total number of released virions in the control 
(tiRNA-free) case with the number of released particles (virion+TIP) in the presence of treatment. This figure 
is plotted by averaging over 250 simulations using parameter values from Table 1 with ba = 1 and br = 1 . The 
initial condition for the MOIs of V = m , T = n is (+)RNAcyt = m , (+)tiRNAcyt = n , and Cp = 180(m + n).
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TIPs as a treatment option during a chronic infection needs to be studied in the context of a within-host model, 
our model provides the foundation for studying such aspects by coupling the intracellular model presented here 
with an intercellular model in a multiscale  approach53, 54.
Discussion
In this paper we have exploited recent insights into PS-mediated assembly in order to propose a novel design for 
TIPs that combines the replicative advantages of existing DIP/TIP strategies over  viruses6, 11, 25 with the benefits 
of PS-mediated assembly. This novel design for TIPs opens up unprecedented therapeutic potential to interfere 
with viral replication and assembly, and misdirect viral resources. We have demonstrated the benefits of this 
combined strategy through stochastic simulations.
The tiRNA designs proposed here are alternatives to other therapeutic strategies exploiting PS-mediated 
assembly, such as small molecular weight compounds targeting the PS:RNA contacts. PS motifs are shared by 
viruses from the same family (e.g. in  picornaviruses32, 55). Some viruses have been repurposed by nature for vital 
functions in the host organism. For instance, captured retroviruses and retrotransposons can be expressed in 
different tissues and at different points during life cycles, such as in neuronal  functioning56, 57 or  placentation58–61. 
Any PS-targeting drugs interfering with virus assembly in related viruses would therefore have to be monitored 
carefully with regards to their effect on other vital functions. tiRNAs, on the other hand, would not pose that risk.
However, they have the same benefits as PS-targeting drugs from the point of view of viral escape. This is 
because in both cases, viral escape would require mutation of the full set (or a significant subset) of the PSs, 
which would result in a significant intermittent fitness loss due to the multiple dispersed nature of the  PSs62, 
making such a transition highly unlikely. The low propensity for therapy resistance is shared by other DIPs/
TIPs, where resistant strains have been shown to be selected against at both individual and population  level25. 
However, our tiRNA design has another advantage: Being stripped of all genetic information, these tiRNAs do 
not pose the risk of recombination. This is in contrast with DIPs that arise via deletion of a portion of the viral 
sequence, such as one genomic segment in the case of the multi-segmented influenza  virus6, and that retain the 
coding capacity for some of the gene products.
As we demonstrate here, tiRNAs show promise as an effective treatment at the intracellular level, especially as 
a prophylactic treatment. Our intracellular model shows that in this case the tiRNA only needs to be as effective at 
packaging and replicating as vRNA to dominate the population of particles released from the infected cell. DVGs 
arising naturally in viruses that assemble via multiple dispersed packaging signals may have only a subset of the 
PS sites and therefore not be optimal at assembly; the possibility to de novo-engineer tiRNAs that not only are 
assembly-competent but are more assembly-efficient than WT, as well as having a replicative advantage, therefore 
constitutes a step-change for antiviral approaches for this group of viruses. As TIPs are indistinguishable from 
WT virus on the particle exterior, they can elicit an immune response (increasing antigen levels), thus priming 
the immune system against a subsequent infection. Multiscale within-host models of the immune response will 
be required to study the impact of this within infected patients, and analyse the impact of TIPs on both acute 
and chronic infections. Furthermore, models of between-host infection dynamics will reveal the consequences 
of any TIP transmission between hosts, and thus potentially reveal additional benefits to the host population 
arising from this. Such models would also enable evaluation of risks associated with the use of  TIPs25, 37, 39.
Figure 4.  Starting treatment 24 h after cell infection has no significant impact even for high replication and 
assembly efficiencies and MOIs. The black curves indicate the average of efficacy over varying MOIs of vRNAs 
and tiRNAs from 1 to 10 ( 1 ≤ V ≤ 10 , 1 ≤ T ≤ 10 ). Blue and red shaded areas show the regions of mean+std 
and mean-std, respectively. Blue and red dashed lines indicates the maximum and minimum efficacy of 
treatment over various MOIs, respectively.
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Methods
Reaction kinetics of the viral life cycle. The first step is the production of polyprotein (PP) using the 
host cell ribosomes (Rib) from the (+)RNA in cytoplasm [(+)RNAcyt]:
Then, the viral proteins are cleaved in a single reaction from the PP:
In the next step, NS5A and NS5Bcyt bind to human factor (HF) and (+)RNAcyt or (+)tiRNAcyt , respectively, and 
these two complexes are imported into the VMS in a second-order reaction:
The imported RNA (tiRNA) forms dsRNA (dstiRNA) and releases NS5B and HF:
Once again the dsRNA (dstiRNA) and NS5BVMS form a complex required to synthesise new (+)RNAVMS 
((+)tiRNAVMS):
(+)RNAVMS ((+)tiRNAVMS ) are either exported into the cytoplasm or assembled into new virions (TIPs) with Cp:
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Parameter values. We use parameter values that have been reported in Aunins et al.41 and are presented 
in Table 1.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information file).
Accession codes
All codes are available in the authors’ GitHub page: github. com/ Mathe matic alCom putat ional Virol ogy/ HCVIn 
trace llula rMode lling.
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